Playback speed
10 seconds
This video is featured in the 2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "GABARNANCE Trial - Gemcitabine + nab-Paclitaxel vs. CRT With S-1 as Neoadjuvant Treatment for Borderline Resectable Pancreatic Cancer"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Masafumi Ikeda
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Masafumi Ikeda
40 views
June 18, 2024
Comments 0
Login to view comments.
Click here to Login